Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives

Left ventricular hypertrophy (LVH) is a strong predictor of adverse cardiovascular outcomes. It is the result of complex mechanisms that include not only an increase in protein synthesis and cell size but also proliferating cardiac progenitor cells and the influx of bone marrow-derived cells develop...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria E. Marketou, Fragiskos Parthenakis, Panos E. Vardas
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2016/5720758
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849411402516660224
author Maria E. Marketou
Fragiskos Parthenakis
Panos E. Vardas
author_facet Maria E. Marketou
Fragiskos Parthenakis
Panos E. Vardas
author_sort Maria E. Marketou
collection DOAJ
description Left ventricular hypertrophy (LVH) is a strong predictor of adverse cardiovascular outcomes. It is the result of complex mechanisms that include not only an increase in protein synthesis and cell size but also proliferating cardiac progenitor cells and the influx of bone marrow-derived cells developing into cardiomyocytes. Stem and progenitor cells are known to contribute to the renewal of adult mammalian cardiomyocytes in case of myocardial injury or pressure and volume overload. They are activated in LVH and play a regulatory role in myocardial repair. They have high proliferative potential and secrete numerous cytokines, growth factors, and microRNAs that play important roles in cell differentiation, cardiac remodeling, and neovascularization. They are mobilized in response to either mechanical or chemical stimuli, hormones, or pharmacologic agents. Another important source of progenitor cells is the epicardial layer. It appears that precursor cells migrate from the epicardium to the myocardium in order to interact with myocardial cells. In addition, migratory cells participate in the formation of almost all cardiac structures in myocardial hypertrophy. Although the pathophysiological mechanisms are still obscure and further studies are required, their properties may open the door to regenerative cell therapy for the prevention of adverse remodeling.
format Article
id doaj-art-66ebb8a1f00a4034b6eaa2d38af86170
institution Kabale University
issn 1687-966X
1687-9678
language English
publishDate 2016-01-01
publisher Wiley
record_format Article
series Stem Cells International
spelling doaj-art-66ebb8a1f00a4034b6eaa2d38af861702025-08-20T03:34:47ZengWileyStem Cells International1687-966X1687-96782016-01-01201610.1155/2016/57207585720758Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New PerspectivesMaria E. Marketou0Fragiskos Parthenakis1Panos E. Vardas2Cardiology Department, Heraklion University Hospital, P.O. Box 1352, 711 10 Crete, GreeceCardiology Department, Heraklion University Hospital, P.O. Box 1352, 711 10 Crete, GreeceCardiology Department, Heraklion University Hospital, P.O. Box 1352, 711 10 Crete, GreeceLeft ventricular hypertrophy (LVH) is a strong predictor of adverse cardiovascular outcomes. It is the result of complex mechanisms that include not only an increase in protein synthesis and cell size but also proliferating cardiac progenitor cells and the influx of bone marrow-derived cells developing into cardiomyocytes. Stem and progenitor cells are known to contribute to the renewal of adult mammalian cardiomyocytes in case of myocardial injury or pressure and volume overload. They are activated in LVH and play a regulatory role in myocardial repair. They have high proliferative potential and secrete numerous cytokines, growth factors, and microRNAs that play important roles in cell differentiation, cardiac remodeling, and neovascularization. They are mobilized in response to either mechanical or chemical stimuli, hormones, or pharmacologic agents. Another important source of progenitor cells is the epicardial layer. It appears that precursor cells migrate from the epicardium to the myocardium in order to interact with myocardial cells. In addition, migratory cells participate in the formation of almost all cardiac structures in myocardial hypertrophy. Although the pathophysiological mechanisms are still obscure and further studies are required, their properties may open the door to regenerative cell therapy for the prevention of adverse remodeling.http://dx.doi.org/10.1155/2016/5720758
spellingShingle Maria E. Marketou
Fragiskos Parthenakis
Panos E. Vardas
Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
Stem Cells International
title Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
title_full Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
title_fullStr Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
title_full_unstemmed Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
title_short Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
title_sort pathological left ventricular hypertrophy and stem cells current evidence and new perspectives
url http://dx.doi.org/10.1155/2016/5720758
work_keys_str_mv AT mariaemarketou pathologicalleftventricularhypertrophyandstemcellscurrentevidenceandnewperspectives
AT fragiskosparthenakis pathologicalleftventricularhypertrophyandstemcellscurrentevidenceandnewperspectives
AT panosevardas pathologicalleftventricularhypertrophyandstemcellscurrentevidenceandnewperspectives